Profile data is unavailable for this security.
About the company
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
- Revenue in USD (TTM)338.93m
- Net income in USD-10.23m
- Incorporated2015
- Employees297.00
- LocationKiniksa Pharmaceuticals LtdClarendon House, 2 Church StreetHAMILTON HM11BermudaBMU
- Phone+1 4417 814399100
- Websitehttps://www.kiniksa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kura Oncology Inc | 0.00 | -181.75m | 1.61bn | 142.00 | -- | 3.44 | -- | -- | -2.23 | -2.23 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -36.00 | -26.04 | -38.16 | -27.45 | -- | -- | -- | -- | -- | -- | 0.0198 | -- | -- | -- | -12.36 | -- | -- | -- |
Nurix Therapeutics Inc | 62.30m | -165.00m | 1.65bn | 284.00 | -- | 4.45 | -- | 26.49 | -2.92 | -2.92 | 1.10 | 5.76 | 0.1446 | -- | -- | 219,376.80 | -38.30 | -33.01 | -46.57 | -39.66 | -- | -- | -264.84 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
BioCryst Pharmaceuticals Inc | 382.24m | -145.93m | 1.68bn | 536.00 | -- | -- | -- | 4.39 | -0.7301 | -0.7301 | 1.90 | -2.30 | 0.7627 | 0.3747 | 6.05 | 713,126.90 | -29.12 | -47.95 | -37.43 | -64.89 | 98.46 | 97.06 | -38.18 | -114.94 | 2.78 | -0.6999 | 2.30 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
Viridian Therapeutics Inc | 288.00k | -228.06m | 1.70bn | 96.00 | -- | 4.32 | -- | 5,911.54 | -4.25 | -4.25 | 0.0053 | 8.29 | 0.0006 | -- | 5.65 | 3,063.83 | -48.67 | -55.59 | -52.32 | -60.32 | -- | -- | -79,185.77 | -5,678.12 | -- | -- | 0.0372 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Bicycle Therapeutics PLC (ADR) | 39.57m | -165.37m | 1.75bn | 284.00 | -- | 2.00 | -- | 44.30 | -3.81 | -3.81 | 0.8962 | 12.67 | 0.0524 | -- | 1.75 | 139,345.10 | -21.88 | -29.45 | -24.15 | -32.98 | -- | -- | -417.88 | -571.36 | -- | -- | 0.0342 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Arvinas Inc | 93.30m | -323.40m | 1.76bn | 445.00 | -- | 2.93 | -- | 18.86 | -5.29 | -5.29 | 1.47 | 8.75 | 0.079 | -- | 12.61 | 209,662.90 | -27.36 | -22.01 | -37.83 | -26.47 | -- | -- | -346.52 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
MannKind Corp | 248.37m | 11.74m | 1.81bn | 414.00 | 184.00 | -- | 104.81 | 7.31 | 0.0359 | 0.0359 | 0.834 | -0.8226 | 0.656 | 2.85 | 9.71 | 599,937.20 | 3.10 | -26.07 | 4.05 | -37.80 | 71.29 | 59.68 | 4.73 | -57.61 | 3.76 | 1.86 | 1.89 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
Kiniksa Pharmaceuticals Ltd | 338.93m | -10.23m | 1.83bn | 297.00 | -- | 4.19 | -- | 5.39 | -0.1788 | -0.1788 | 4.68 | 6.12 | 0.6602 | 1.41 | 15.03 | 1,141,179.00 | -1.99 | -16.49 | -2.29 | -18.72 | 87.73 | -- | -3.02 | -53.64 | 3.16 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
Rocket Pharmaceuticals Inc | 0.00 | -253.26m | 1.83bn | 268.00 | -- | 4.77 | -- | -- | -2.79 | -2.79 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -55.77 | -35.26 | -60.57 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0522 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
Mirum Pharmaceuticals Inc | 264.38m | -109.16m | 1.86bn | 294.00 | -- | 8.09 | -- | 7.03 | -2.40 | -2.40 | 5.81 | 4.81 | 0.4788 | 5.06 | 5.52 | 1,001,424.00 | -19.77 | -38.93 | -23.38 | -44.88 | 72.27 | -- | -41.29 | -190.71 | 3.09 | -- | 0.573 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Recursion Pharmaceuticals Inc | 49.64m | -374.93m | 1.92bn | 500.00 | -- | 3.27 | -- | 38.67 | -1.63 | -1.63 | 0.2155 | 2.08 | 0.0688 | -- | 17.80 | 99,270.00 | -51.98 | -- | -60.35 | -- | 17.15 | -- | -755.37 | -- | -- | -- | 0.0504 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
Akero Therapeutics Inc | 0.00 | -204.18m | 1.95bn | 61.00 | -- | 2.44 | -- | -- | -3.41 | -3.41 | 0.00 | 11.53 | 0.00 | -- | -- | 0.00 | -26.71 | -37.73 | -27.66 | -40.13 | -- | -- | -- | -- | -- | -- | 0.042 | -- | -- | -- | -35.46 | -- | -- | -- |
Soleno Therapeutics Inc | 0.00 | -65.41m | 2.01bn | 33.00 | -- | 7.06 | -- | -- | -2.43 | -2.43 | 0.00 | 7.31 | 0.00 | -- | -- | 0.00 | -39.04 | -53.90 | -41.25 | -61.85 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -62.00 | -- | -- | -- |
Novavax Inc | 987.67m | -294.33m | 2.07bn | 1.54k | -- | -- | -- | 2.09 | -2.76 | -2.76 | 7.41 | -2.70 | 0.5638 | 21.98 | 4.63 | 640,095.30 | -16.80 | -46.06 | -78.53 | -269.57 | 63.67 | -- | -29.80 | -75.94 | 1.03 | -18.79 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
Neumora Therapeutics Inc | 0.00 | -274.18m | 2.07bn | 108.00 | -- | 5.42 | -- | -- | -1.66 | -1.66 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -71.73 | -- | -76.67 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fairmount Funds Management LLCas of 31 Mar 2024 | 3.20m | 7.92% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.09m | 7.65% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.93m | 7.25% |
Baker Bros. Advisors LPas of 05 Jun 2024 | 2.86m | 7.08% |
Rubric Capital Management LPas of 31 Mar 2024 | 2.20m | 5.43% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.89m | 4.67% |
Pictet Asset Management SAas of 31 Mar 2024 | 1.46m | 3.61% |
Braidwell LPas of 31 Mar 2024 | 1.39m | 3.44% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 958.81k | 2.37% |
Geode Capital Management LLCas of 30 Jun 2024 | 848.89k | 2.10% |